drugset / Trial / NCT05894707
Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
RandomizedSequentialDouble-blindTreatment
Summary
The goal of clinical trial is to evaluate the safety and tolerability of SCT650C in healthy participants.
Timeline
- Start
- 2023-06
- Primary completion
- 2023-11
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCT650C | Monoclonal antibody | 20 mg | — |
| Subject | SCT650C | Monoclonal antibody | 40 mg | — |
| Subject | SCT650C | Monoclonal antibody | 80 mg | — |
| Subject | SCT650C | Monoclonal antibody | 160 mg | — |